Company Overview - Alzamend Neuro Inc. has partnered with Massachusetts General Hospital to conduct a Phase 2 study of AL001 for treating post-traumatic stress disorder (PTSD) [1][2] - The company aims to assess the comparative increase in lithium levels in the brain compared to commonly marketed lithium salts among PTSD patients [2] Clinical Trial Details - The objective of the trial is to predict the minimum dose necessary for AL001 to achieve effectiveness and safety comparable to established lithium salts [2] - The study is expected to help meet regulatory safety standards through the Section 505(b)(2) pathway for FDA approval [2] Market Performance - Following the announcement of the partnership and clinical trial, Alzamend Neuro's stock (ALZN) increased by 267.7%, reaching $7.50 [2]
Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details